For example, the incidence of grade 4 neutropenia is significantly higher, while median PFS and OS are significantly shorter in non-small cell lung cancer patients receiving irinotecan with UGT1A1*6 homozygous mutation compared to the heterozygous mutation or wild-type allele [16]. Here, UGT1A1 is linked to neutropenia.